Key Highlights
- Genmab (NASDAQ:GMAB) rose 60.44% in a month to USD 55.77 after Phase 3 data showed a survival hazard ratio of 0.50. Netskope (NASDAQ:NTSK) rose 54.14% to USD 26.42 after fiscal second quarter revenue growth of 29%.
- Bending Spoons (NASDAQ:BSP) rose 44.80% to USD 47.48, with a reported USD 330 million Berkshire Hathaway placement on October 14, 2026. Range Resources (NYSE:RRC) rose 42.70% to USD 55.03 on EQT's all-stock deal valued at about USD 12.8 billion.
- PTC (NASDAQ:PTC) rose 41.68% to USD 194.18, about 5.6% below Schneider Electric's USD 205 cash offer announced October 5, 2026, with closing expected by the third quarter of 2027, simple arithmetic on two published prices.
- The five moves have different causes: a trial result, a results beat, a reported placement and two takeover agreements, so the risks differ for each. All figures are published market data as of October 28, 2026.
Genmab (NASDAQ:GMAB): Up 60.44% on Phase 3 Data
The LiGeR-HN1 study tests petosemtamab plus pembrolizumab against pembrolizumab alone in first-line PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma. The company said both overall survival and objective response rate improved with statistical significance at the first interim analysis, with no new safety signals. A hazard ratio of 0.50 means a roughly 50% lower risk of death at any point, compared with the control arm. Interim analyses can end a study early when results cross a prespecified boundary. Genmab (NASDAQ:GMAB) said it plans to engage global regulators and present full data at a future medical meeting. The shares closed the session up 24.85% at USD 55.77 in published market data, after intraday coverage had shown a smaller gain near 16%, so the final size of the move should be read from official closing data. Petosemtamab came from the Merus acquisition, which Genmab agreed in September 2025 at USD 97 a share in cash, about USD 8 billion, a 41% premium. The asset holds two FDA Breakthrough Therapy designations, and the company then targeted at least USD 1 billion of annual sales by 2029.
Netskope (NASDAQ:NTSK): Up 54.14% After Strong Results
Netskope (NASDAQ:NTSK) reported its quarter ended July 31, 2026 on September 2. Revenue was USD 220.5 million and annual recurring revenue USD 899 million, with strength across regions, especially Europe and Asia Pacific. The non-GAAP operating margin was negative 9% and free cash flow was negative USD 29.8 million, so the company is still spending ahead of revenue. Management guided the third quarter to USD 227 million to USD 229 million of revenue and raised fiscal 2027 revenue guidance to USD 888 million to USD 892 million, with a free cash flow margin near 2%. Published commentary dated October 7 said about one third of its AI security pipeline had reached proof of concept. The move coincided with a wider recovery in software shares. A J.P. Morgan industry note dated October 8 said the software ETF had gained about 21% since the end of June, with infrastructure software leading on earnings upgrades. Higher estimates for the sector lifted the multiples investors paid for growth, so Netskope (NASDAQ:NTSK) benefited from sentiment as well as from its own report.
Bending Spoons (NASDAQ:BSP): Up 44.80% With a Reported Placement
Bending Spoons (NASDAQ:BSP) listed in July 2026. On October 14 it disclosed a private placement of 10 million shares to Berkshire Hathaway at USD 33.00, which with the earlier IPO stake totals about USD 930 million and roughly 4% of the company, according to published coverage of the filing. The shares jumped 41.2% to USD 53.46 that day, but no filing explains the move, so the placement and rally are concurrent, not proven cause and effect. The placement price sits far below the trading price, a gap that coverage does not explain, so the filing itself should be checked. The company describes itself as an acquirer that buys digital products and runs them for profit, which makes deal flow central to results. Floating-rate debt and thin organic growth are the main risks, and a recent listing has limited trading history. Second quarter revenue rose 126% to USD 704 million, but organic growth was only 3%, so purchases drive the numbers.
Range Resources (NYSE:RRC): Up 42.70% on the EQT Deal
The agreement announced on October 26, 2026 would create the largest US natural gas producer. In an all-stock deal, shareholders receive shares of the buyer at a fixed exchange ratio, so the value they hold moves with EQT's price until closing. Published coverage implied about USD 54.91 for each Range Resources (NYSE:RRC) share, and the company filing did not state a price or exchange ratio, so those figures are reported, not verified. The shares closed higher on both October 26 and 27, and Texas Capital cut the rating to Hold on October 27, a sign that the upside is now tied to the deal. The combined group would hold large acreage in the Appalachian basin, where pipeline capacity, not geology, often limits how much gas reaches buyers. Results released October 27 showed net income of USD 175 million, GAAP diluted earnings of USD 0.75 a share and adjusted earnings of USD 0.81.
PTC (NASDAQ:PTC): Up 41.68% on a Cash Offer
The all-cash agreement values PTC (NASDAQ:PTC) at about USD 22.6 billion in equity and USD 23.7 billion including debt, and the premium is 46.1% over the 30-trading-day average price. Reports of buyout interest had pushed the shares up before the announcement. Schneider plans roughly EUR 22 billion of cash consideration under a committed bridge facility from Morgan Stanley and Societe Generale, to be refinanced with about EUR 5 billion to EUR 6 billion of equity and EUR 16 billion to EUR 17 billion of debt, as published accounts describe it. PTC makes computer-aided design and product lifecycle software used by manufacturers, which is why an industrial group wants to own it. A competing bid is possible in theory, but none has been reported, and approvals in several jurisdictions could take many months, which keeps a spread in the price. In a cash deal the target usually trades slightly under the offer, because holders wait until closing and carry the risk it fails.
Where Things Stand
The answer is that five separate catalysts, not one theme, drove these gains. Genmab (NASDAQ:GMAB) gained on Phase 3 trial data and Netskope on a results beat. Bending Spoons (NASDAQ:BSP) gained on a reported Berkshire Hathaway placement. Range Resources (NYSE:RRC) gained on EQT's all-stock terms. PTC (NASDAQ:PTC) gained on Schneider Electric's cash offer. The two deal stocks now trade near their offer values, so their next moves depend on closing, while the others depend on delivery. These are snapshots as of October 28, 2026. The risks described above also apply to Genmab (NASDAQ:GMAB). The next company disclosures from Bending Spoons (NASDAQ:BSP) are the key test. Readers can check the latest company filings for PTC (NASDAQ:PTC).





_11_20_2026_12_38_15_908731.jpg)
Please wait processing your request...